
Sign up to save your podcasts
Or


Semaglutide 2.4 mg weekly led to significant resolution of MASH and reduction in fibrosis after 72 weeks 🌟🧬.
Patients lost more weight ⚖️, showed better liver markers 📉, and had improved metabolic profiles 💉.
GI side effects were common 🤢, but no new safety signals emerged ✅.
Promising dual-action therapy for liver and cardiometabolic health! ❤️🩺
By Dr RR Baliga, MD, MBA5
66 ratings
Semaglutide 2.4 mg weekly led to significant resolution of MASH and reduction in fibrosis after 72 weeks 🌟🧬.
Patients lost more weight ⚖️, showed better liver markers 📉, and had improved metabolic profiles 💉.
GI side effects were common 🤢, but no new safety signals emerged ✅.
Promising dual-action therapy for liver and cardiometabolic health! ❤️🩺

905 Listeners

3,381 Listeners

20,577 Listeners